Acquired tumor cell resistance to sunitinib by increased invasion and epithelial-mesenchymal transition in LL/2 murine lung cancer
Metrics: PDF 585 views | HTML 1002 views | ?
Yang Du1,*, Jia-Qi Liu1,*, Jie Tang1, Jun Ge1, Ye Chen1, Ke Cheng1, Jing Ding1, Zhi-Ke Li1 and Ji-Yan Liu1
1Department of Medical Oncology, Cancer Center, State Key Laboratory of Biotherapy, West China Hospital, West China Medical School, Sichuan University, GuoXue Xiang, Chengdu 610041, Sichuan Province, China
*These authors have contributed equally to this work
Ji-Yan Liu, email: firstname.lastname@example.org
Keywords: sunitinib, drug-resistance, lung cancer, increased invasion, epithelial-mesenchymal transition
Received: March 31, 2017 Accepted: June 05, 2017 Published: July 17, 2017
Objective: This study aims to investigate biological behavior changes in a murine lung cancer cell characterized by acquired resistance to sunitinib, a potent inhibitor of multiple-targeted receptor tyrosine kinase.
Methods: A lung cancer cell line resistant to sunitinib (LL/2-R) was developed from its parental cell line (LL/2-P). Differences in biological characteristics and associated molecular profiles between these two cells were compared in vitro and in vivo.
Results: LL/2-R cells showed an approximately 5-fold higher IC50 of sunitinib than LL/2-P cells and exhibited a reduced growth inhibition following sunitinib treatment compared with LL/2-P. In LL/2-R cells and tumors, increased migration, invasion and metastasis were observed, along with upregulation of MMP-2 and MMP-9. We also analyzed the molecular profiles involved in EMT, and found that E-cadherin was downregulated in LL/2-R tumors, and vimentin was upregulated in LL/2-R cells and tumors, along with β-catenin translocating to the nuclei in LL/2-R cells. Furthermore, transcriptional factors mediated EMT, snail and twist, and the secretion of TGFβ1 also increased in LL/2-R cells and tumors.
Conclusions: We established a sunitinib-resistant lung cancer cell line and confirmed its drug-resistance to sunitinib in vivo. Our results implied that increased invasion and EMT may associate with the acquisition of resistant phenotype to sunitinib in cancer cells.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.